Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock.

ESPR has been the topic of several other reports. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics has an average rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Trading Up 2.3 %

Shares of ESPR opened at $2.20 on Thursday. The stock has a market capitalization of $433.49 million, a price-to-earnings ratio of -3.44 and a beta of 1.03. The firm has a fifty day simple moving average of $2.46 and a 200 day simple moving average of $2.18. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same period in the prior year, the company posted ($0.37) EPS. As a group, research analysts predict that Esperion Therapeutics will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

A number of large investors have recently bought and sold shares of the company. Foundations Investment Advisors LLC grew its stake in Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 9,872 shares in the last quarter. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics during the fourth quarter worth about $55,000. SG Americas Securities LLC grew its stake in Esperion Therapeutics by 96.6% during the fourth quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 74,433 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Esperion Therapeutics by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after purchasing an additional 19,588 shares in the last quarter. Finally, Eaton Financial Holdings Company LLC acquired a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $73,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.